Showing 142 Results
Value in Health highlights commentary contributed by NPC's John O'Brien and NPC board member Jan E. Hansen on the implications of the Medicare Drug Price Negotiation Program.
NPC writes in Health Affairs Forefront about the unintended consequences of the IRA and the impact of the changing economic incentives for clinical development programs.
The drug price-related provisions of the Inflation Reduction Act make the case for including dynamic drug pricing in cost-effectiveness analysis even more compelling.
Michael Pratt named Chief Communications Officer as NPC boosts research and engagement capabilities
In this issue: Evidence and drug pricing policy, wages and access to care, the (minimal) costs of expanding pre-deductible coverage.
In this issue: Improving benefit design, patient perspectives on innovation, resources to guide health spending research and policy-making & more.
In this issue: Measuring the impact of innovation, new resources to navigate health spending research and policy-making, good practices for HDHPs and a busy spring event calendar.
In this issue: We offer a new resource on the myth of the "average" patient, outline key challenges in value assessment and health technology assessment, and highlight two upcoming webinars.
NPC announced the appointment of Sharon Phares, PhD, MPH, as Chief Scientific Officer.
In this issue: Explore the pitfalls in the most recent drug pricing deal, regulation that's led to improvements in employee benefits and keys to improving equity in health coverage.
NPC announced Steven Romano, MD, Executive Vice President and Chief Scientific Officer, Mallinckrodt Pharmaceuticals, has been elected Chair of NPC’s Board of Directors for 2021-2022.
In this issue: Explore drug pricing and innovation, patient input in health benefit design, the research infrastructure to examine social determinants of health and upcoming events.
NPC joined a group of 14 health care organizations in and around Washington, D.C., in issuing a joint statement making COVID-19 vaccination a condition of returning to work in their respective…
In this issue: meet NPC's new president and CEO, learn how we can tackle low-value care, what we need to know about the budget cap dilemma, and catch up on news you might have missed!
Veteran drug pricing and health policy expert John M. O’Brien, Pharm.D., MPH, has been appointed as president and chief executive officer of the National Pharmaceutical Council, effective June 1,…
The American Journal of Managed Care® (AJMC®) and Pharmacy Times® today announced that the National Pharmaceutical Council (NPC) has joined their Strategic Alliance Partnership (SAP) programs.